{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:38:39Z","timestamp":1789141119684,"version":"build-2803163510"},"reference-count":58,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002385","name":"Ministry of Higher Education","doi-asserted-by":"publisher","award":["4-518\/17.004"],"award-info":[{"award-number":["4-518\/17.004"]}],"id":[{"id":"10.13039\/501100002385","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Else Kr\u00f6ner-Fresenius Foundation"},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.bbmt.2019.03.004","type":"journal-article","created":{"date-parts":[[2019,3,13]],"date-time":"2019-03-13T03:11:11Z","timestamp":1552446671000},"page":"1281-1292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Clearance of Hematologic Malignancies by Allogeneic Cytokine-Induced Killer Cell or Donor Lymphocyte Infusions"],"prefix":"10.1016","volume":"25","author":[{"given":"Michael","family":"Merker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Salzmann-Manrique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Katzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Huenecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Bremm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrzad","family":"Bakhtiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Willasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Jarisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Soerensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ansgar","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Meisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gesine","family":"Bug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halvard","family":"Bonig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Klingebiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Rettinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2019.03.004_bib0001","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","article-title":"Graft-versus-leukemia reactions after bone marrow transplantation","volume":"75","author":"Horowitz","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0002","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1182\/blood.V96.8.2712","article-title":"Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia","volume":"96","author":"Dazzi","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0003","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0004","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0005","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1182\/blood-2005-08-3373","article-title":"A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3\/CD28 costimulation","volume":"107","author":"Porter","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0006","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1136\/gut.28.2.113","article-title":"Immunotherapy for cancer: the use of lymphokine activated killer (LAK) cells","volume":"28","author":"Fagan","year":"1987","journal-title":"Gut"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0007","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0008-8749(91)90273-E","article-title":"Anti-CD3 antibody-induced activated killer cells: cytokines as the additional signals for activation of killer cells in effector phase to mediate slow lysis","volume":"135","author":"Ting","year":"1991","journal-title":"Cell Immunol"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0008","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/00002371-200307000-00005","article-title":"Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients","volume":"26","author":"Dudley","year":"2003","journal-title":"J Immunother"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0009","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1200\/JCO.2006.07.1100","article-title":"Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma","volume":"24","author":"Mackensen","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0010","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/blood-2004-06-2482","article-title":"Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy","volume":"105","author":"Powell","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0011","doi-asserted-by":"crossref","first-page":"5092","DOI":"10.4049\/jimmunol.167.9.5092","article-title":"Targeting of tumor cells for human gamma-delta T cells by nonpeptide antigens","volume":"167","author":"Kato","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0012","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/ijc.1198","article-title":"Anti-tumor effects of human peripheral gamma-delta T cells in a mouse tumor model","volume":"92","author":"Zheng","year":"2001","journal-title":"Int J Cancer"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0013","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00262-006-0199-6","article-title":"Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study","volume":"56","author":"Kobayashi","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0014","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1007\/s00262-008-0491-8","article-title":"Phase-I study of Innacell gamma-delta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma","volume":"57","author":"Bennouna","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0015","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0016","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/sj.bmt.1704810","article-title":"Use of natural killer cells in hematopoietic stem cell transplantation","volume":"35","author":"Passweg","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0017","doi-asserted-by":"crossref","first-page":"9571","DOI":"10.1073\/pnas.0503726102","article-title":"Central memory self\/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells","volume":"102","author":"Klebanoff","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0018","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1517\/14712591003610622","article-title":"Enhancing adoptive immunotherapy of cancer","volume":"10","author":"Westwood","year":"2010","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0019","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nri2073","article-title":"Prospects for the use of NK cells in immunotherapy of human cancer","volume":"7","author":"Ljunggren","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0020","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1084\/jem.174.1.139","article-title":"Use of a SCID mouse\/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity","volume":"174","author":"Schmidt-Wolf","year":"1991","journal-title":"J Exp Med"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0021","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1365-2141.1994.tb08297.x","article-title":"Propagation of large numbers of T cells with natural killer cell markers","volume":"87","author":"Schmidt-Wolf","year":"1994","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0022","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.4049\/jimmunol.153.4.1687","article-title":"A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency","volume":"153","author":"Lu","year":"1994","journal-title":"J Immunol"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0023","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1182\/blood.V92.9.3318","article-title":"Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice","volume":"92","author":"Hoyle","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0024","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/ijc.21994","article-title":"Cytokine-induced killer cells against autologous CLL: direct cytotoxic effects and induction of immune accessory molecules by interferon-gamma","volume":"119","author":"Kornacker","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0025","first-page":"1108","article-title":"Expansion of CD3+CD56+ cytotoxic cells from patients with chronic lymphocytic leukemia: in vitro efficacy","volume":"85","author":"Lefterova","year":"2000","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0026","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1046\/j.1365-2141.2002.03247.x","article-title":"Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts","volume":"116","author":"Linn","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0027","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/S1083-8791(01)70014-6","article-title":"Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma","volume":"7","author":"Verneris","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0028","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2003-06-2125","article-title":"Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells","volume":"103","author":"Verneris","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0029","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1006\/cimm.1996.0094","article-title":"Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells","volume":"169","author":"Schmidt-Wolf","year":"1996","journal-title":"Cell Immunol"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0030","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s002620000111","article-title":"Resistance of ex vivo expanded CD3+CD56+ T cells to Fas-mediated apoptosis","volume":"49","author":"Verneris","year":"2000","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0031","first-page":"1673","article-title":"Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells","volume":"21","author":"Schmidt-Wolf","year":"1993","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0032","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1182\/blood.V86.9.3493.bloodjournal8693493","article-title":"Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+CD56+ killer cells","volume":"86","author":"Mehta","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0033","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1126\/science.7518614","article-title":"Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity","volume":"265","author":"K\u00e4gi","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0034","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1182\/blood-2011-02-336321","article-title":"Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity","volume":"118","author":"Pievani","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0035","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.bbmt.2016.10.006","article-title":"Pre-emptive immunotherapy for clearance of molecular disease in childhood acute lymphoblastic leukemia after transplantation","volume":"23","author":"Rettinger","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0036","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.3324\/haematol.2015.138016","article-title":"Interleukin-15-activated cytokine-induced killer cells may sustain remission in leukemia patients after allogeneic stem cell transplantation: feasibility, safety and first insights on efficacy","volume":"101","author":"Rettinger","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0037","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1200\/JCO.2004.05.198","article-title":"Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy?","volume":"22","author":"Bader","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0038","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1038\/sj.leu.2402515","article-title":"T cell receptor gamma gene rearrangements as targets for detection of minimal residual disease in acute lymphoblastic leukemia by real-time quantitative PCR analysis","volume":"16","author":"van der Velden","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0039","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.leu.2404586","article-title":"Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data","volume":"21","author":"van der Velden","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0040","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/bmt.2009.204","article-title":"Multivariate analyses of immune reconstitution in children after allo-SCT: risk-estimation based on age-matched leukocyte sub-populations","volume":"45","author":"Koenig","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0041","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1600-0609.2008.01052.x","article-title":"Age-matched lymphocyte subpopulation reference values in childhood and adolescence: application of exponential regression analysis","volume":"80","author":"Huenecke","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0042","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.bbmt.2007.12.487","article-title":"Risk-adjusted outcome measurement in pediatric allogeneic stem cell transplantation","volume":"14","author":"Matthes-Martin","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0043","series-title":"R: a language and environment for statistical computing","year":"2014"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0044","unstructured":"Therneau T. A package for survival analysis in S. version 2.38. Available at: https:\/\/cran.r-project.org\/package=survival. Accessed December 15, 2018."},{"key":"10.1016\/j.bbmt.2019.03.004_bib0045","unstructured":"Gray B. cmprsk: Subdistribution analysis of competing risks. R package version 2.2-7. Available at: http:\/\/www.r-project.org\/. Accessed December 15, 2018."},{"key":"10.1016\/j.bbmt.2019.03.004_bib0046","unstructured":"Pinheiro J, Bates D, DebRoy S, Sarkar D; R Core Team. nlme: Linear and nonlinear mixed effects models. R package version 3.1-137. Available at: https:\/\/CRAN.R-project.org\/package=nlme. Accessed December 15, 2018."},{"key":"10.1016\/j.bbmt.2019.03.004_bib0047","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2217\/imt.15.100","article-title":"Strategies for improving the efficacy of donor lymphocyte infusion following stem cell transplantation","volume":"8","author":"Stamouli","year":"2016","journal-title":"Immunotherapy"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.exphem.2009.01.010","article-title":"Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes","volume":"37","author":"Franceschetti","year":"2009","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0049","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1172\/JCI4992","article-title":"Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin-12","volume":"102","author":"Yang","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0050","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1182\/blood-2007-06-092817","article-title":"In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity","volume":"112","author":"Nishimura","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0051","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3324\/haematol.11132","article-title":"Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study","volume":"92","author":"Introna","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0052","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.bbmt.2011.05.012","article-title":"Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation","volume":"17","author":"Laport","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0053","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/bmt.2011.202","article-title":"The anti-tumor activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies","volume":"47","author":"Linn","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0054","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/j.bbmt.2017.07.005","article-title":"Phase II study of sequential infusion of donor lymphocyte infusion and cytokine-induced killer cells for patients relapsed after allogeneic hematopoietic stem cell transplantation","volume":"23","author":"Introna","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0055","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1054\/blre.2001.0157","article-title":"Haploidentical stem cell transplantation in leukemia","volume":"15","author":"Aversa","year":"2001","journal-title":"Blood Rev"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0056","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1182\/blood-2002-02-0350","article-title":"Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect","volume":"100","author":"Farag","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0057","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1080\/14653240601078721","article-title":"Natural killer cell alloreactivity and haplo-identical hematopoietic transplantation","volume":"8","author":"Ruggeri","year":"2006","journal-title":"Cytotherapy"},{"key":"10.1016\/j.bbmt.2019.03.004_bib0058","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.bbmt.2010.05.015","article-title":"Feasibility and safety of adoptive immunotherapy with CIK cells after cord blood transplantation","volume":"16","author":"Introna","year":"2010","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879119301569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879119301569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:08:02Z","timestamp":1761059282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879119301569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":58,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S1083879119301569"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2019.03.004","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clearance of Hematologic Malignancies by Allogeneic Cytokine-Induced Killer Cell or Donor Lymphocyte Infusions","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2019.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}